Glenmark’s Ryaltris ‘Ahead Of The Game’ In Markets, COVID-19 Nasal Spray Coming

There is momentum for Glenmark’s Ryaltris across new launch markets internationally, with FY2023 and FY2024 seen as important years for revenue scale-up. A partnered nitric oxide nasal spray for COVID-19 faces trial recruitment challenges in India but the firm hopes to be able to debut the product this year.

earnings delta
Multiple growth levers for Glenmark in coming year • Source: Alamy

Traction for the respiratory portfolio, including commercialization hopes for one yet undisclosed “big product” in Europe, and the anticipated debut of a partnered COVID-19 nasal spray in India and other markets, point to an action-packed 2022 for Glenmark Pharmaceuticals Limited amid pandemic uncertainties.

Glenmark’s Ryaltris (olopatadine/mometasone furoate nasal spray) appears to have made significant strides in recent launch markets globally and the Indian...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip